Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,514.69
(
-0.06%
)
US TECH 100
29,128.24
(
-0.28%
)
Dow Jones
50,638.96
(
0.35%
)
Brent Oil
92.08
(
-5.06%
)
Bitcoin
74,885.15
(
-1.27%
)
News Focus
News Focus
Post# of 448110
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Biobillionair

Send PM Follow Ignore
Followers 232
Posts 26887
Boards Moderated 0
Alias Born 01/12/2013

Biobillionair

Re: Sam81 post# 163267

Tuesday, 11/27/2018 9:35:52 AM

Tuesday, November 27, 2018 9:35:52 AM

Post# of 448110
Sam- I understand Amarin’s current strategy, but it doesn’t go far enough to protect patients. This was an unknown due to no information regarding when sNDA would be filed or if R-I SPA had an immediate Anchor like label.

Neither an immediate label or timely sNDA is now expected, this has created a NEW issue, the safety of patients.

Amarin MUST expand First promotion even if leading to FDA legal battle, the results of R-I are too strong to stifle. Patients need this drug!!!

BB

I do not pump Amarin stock. I am not an Amarin cheerleader. If I see something I don't like I make it known. Patients come first, always!!!

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AMRN News
More AMRN News